Lahm, TimKawut, Steven M.2018-03-092018-03-092017-08-03Lahm, T., & Kawut, S. M. (2017). Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research. The European Respiratory Journal, 50(2). https://doi.org/10.1183/13993003.00983-20170903-1936https://hdl.handle.net/1805/15428Pulmonary arterial hypertension (PAH) is a sexually dimorphic disease that affects women more than men. Several pre-clinical and clinical studies identified 17β-oestradiol (E2), the most abundant female sex hormone, and/or its metabolite 16α-hydroxyoestrone as disease mediators in PAH (reviewed by Lahm et al. [1], and Foderaro and Venteuolo [2]). A recent case–control study even demonstrated significantly higher levels of E2 in men with PAH compared to controls [3]., Inhibition of oestrogen signalling in PAH is currently being studied clinically but several questions remain http://ow.ly/G7xK30cPN5Men-USPublisher Policyoestrogenpulmonary arteriessexhypertensiondrugsArticle